Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Mar;113(3):471-472.
doi: 10.1002/cpt.2772. Epub 2022 Nov 22.

Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!

Fabienne Thomas  1 , Manon Launay  2 , Jérôme Guitton  3 , Marie-Anne Loriot  4   5 , Jean-Christophe Boyer  6 , Vincent Haufroid  7 , Marie-Christine Etienne-Grimaldi  8 , Bernard Royer  9   10 ; GPCO-UNICANCER Group
Affiliations
Comment

Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!

Fabienne Thomas et al. Clin Pharmacol Ther. 2023 Mar.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. de With, M. et al. Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study. Clin. Pharmacol. Ther. 112, 62-68 (2022).
    1. Maillard, M. et al. Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency. Br. J. Clin. Pharmacol. (2022). https://doi.org/10.1111/bcp.15536. [e-pub ahead of print].
    1. Jacobs, B.A.W. et al. Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. J. Pharm. Biomed. Anal. 126, 75-82 (2016).
    1. Capiau, S., Van Landschoot, A., Reyns, T. & Stepman, H. Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma. Clin. Chem. Lab. Med. 60, e112-e115 (2022).
    1. Recommandations et référentiels, INCa, HAS, décembre 2018. Recherche d'’un déficit en dihydropyrimidine deshydrogénase visant à prévenir certaines toxicités sévères associées aux traitements par fluoropyrimidines. <https://www.has-sante.fr/portail/upload/docs/application/pdf/2018-12/rec....

LinkOut - more resources